Pharmaceuticals News

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with...

MONTAUK, N.Y., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Montauk Brewing Co., the coastal lifestyle and craft beer brand by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) that captures the laid-back energy...

Independent Data Monitoring Committee (IDMC) recommends recruitment of the next two patients at the first dose levelFirst patient completed the planned first treatment cycle with no serious adverse...

Hovedpunkter: Den Uavhengige Dataovervåkingskomiteen (IDMC) anbefaler rekruttering av de to neste pasientene på det første dosenivåetFørste pasient fullførte den første behandlingssyklusen uten...

LONDON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production and distribution and a division of Tilray Brands, Inc. (“Tilray”)...

   Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline ...

REHOVOT, Israel and HOBOKEN, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for...

Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics Slate’s lead product candidate, SLTE-1009, is a clinical stage,...

Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining...

– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15...